Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Total Current Liabilities came in at $1.5 billion in Q2 2026, up 16.27% YoY from $1.3 billion in Q2 2025, and up 12.08% on a QoQ basis from $1.3 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Total Current Liabilities data on file, last reported at $1.5 billion in Q2 2026.
- Quarterly Total Current Liabilities rose 16.27% year-over-year to $1.5 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 16.27% YoY) and the FY2025 annual result came in at $1.5 billion, up 23.61% from the prior year.
- Total Current Liabilities rose to $1.5 billion in Q2 2026, from $1.3 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $1.6 billion in Q3 2025 to a low of $606.0 million in Q1 2022.
- A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities climbed 10.38% — and 2024, when it surged 39.85%.
- Tracing ALNY's Total Current Liabilities over 5 years: stood at $767.9 million in 2022, then increased by 26.03% to $967.8 million in 2023, then rose by 22.58% to $1.2 billion in 2024, then increased by 23.61% to $1.5 billion in 2025, then increased by 3.15% to $1.5 billion in 2026.
- The last three Total Current Liabilities figures came in at $1.5 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.51 Bn |
| Mar 31, 2026 | 1.35 Bn |
| Dec 31, 2025 | 1.47 Bn |
| Sep 30, 2025 | 1.56 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Mar 31, 2025 | 1.08 Bn |
| Dec 31, 2024 | 1.19 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 941.71 Mn |
| Dec 31, 2023 | 967.79 Mn |
| Sep 30, 2023 | 949.79 Mn |
| Jun 30, 2023 | 788.64 Mn |
| Mar 31, 2023 | 673.39 Mn |
| Dec 31, 2022 | 767.92 Mn |
| Sep 30, 2022 | 772.79 Mn |
| Jun 30, 2022 | 657.69 Mn |
| Mar 31, 2022 | 605.96 Mn |
| Dec 31, 2021 | 695.71 Mn |
| Sep 30, 2021 | 610.66 Mn |